MetacrineSciences

MetacrineSciences

A biotechnology company with a focus on pharmaceuticals that treat liver and gastrointestinal diseases. It was founded in 2014 and is located in San Diego, California.

About

Metacine is a San Diego-based company that specializes in the research and development of drugs for liver and gastrointestinal (GI) diseases, such as nonalcoholic steatohepatitis (NASH), irritable bowel syndrome with diarrhea (IBS-D), and inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease.

Product

The company has multiple programs running for the research and development of its products. Its FXR

agonist program is designed for NASH and IBD and is in the Phase 2 and Phase 1 of clinical trials for each respective disease. The SSAO/VAP-1 Inhibitor program is an inflammatory target and is in the pre-clinical stage of development. Its HSD17B13 inhibitor is also for NASH and is in the lead optimizations stage.

The drug from its FXR agonist program is called MET409 and has seen success when it was administered in different dosages along with a placebo group. When the drug was dosed at 80 milligrams to patients, researchers saw a 55% reduction in relative mean liver fat content in the patients.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Metacrine funding round, June 2018
65,000,000
June 2018
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Preston Klassen, M.D., MHS

President and CEO

Trisha Millican

CFO

Further reading

Title
Author
Link
Type
Date

Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients

Web

January 22, 2020

Metacrine Secures $50 Million Growth Capital Facility from K2 HealthVentures

Web

September 18, 2019

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.